SPHERE - Study of Perinatal, paediatric and adolescent Health : Epidemiological Research and Evaluation
Equipe constitutive du CERPOP, UMR1295, unité mixte de recherche Inserm – Université Toulouse III Paul Sabatier
Mélanie ARAUJO •  ITA

 

2022
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Lacroix I. Topical sertaconazole during pregnancy and risk of adverse pregnancy outcome and major congenital anomalies: Comparative study in the EFEMERIS database. Mycoses. 2022 Apr;65(4):481-489. doi: 10.1111/myc.13422.
     
  2. Benevent J, Hurault-Delarue C, Araujo M, Revet A, Sommet A, Lacroix I, Damase-Michel C. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study. Front Psychiatry. 2022 Mar 22;13:795890. doi: 10.3389/fpsyt.2022.795890.
     
  3. Benevent J, Araujo M, Beau AB, Sicard D, Sommet A, Hurault-Delarue C, Lacroix I, Damase-Michel C. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database. Infection. 2022 Jun 11. doi: 10.1007/s15010-022-01861-4. Epub ahead of print.
     
  4. Vabre C, Araujo M, Damase-Michel C, Hurault-Delarue C, Lacroix I. Initial data on the safety of metopimazine during pregnancy and the risk of major birth defects and pregnancy loss - An observational study using the EFEMERIS database. Therapie. 2022 Jul-Aug;77(4):405-412. doi: 10.1016/j.therap.2021.09.006.

2021
  1. Araujo M, Vabre C, Benevent J, Sommet A, Damase-Michel C, Hurault-Delarue C, Lacroix I. Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure: A Study in the EFEMERIS Database. Drug Saf. 2021 Jul;44(7):787-796. doi: 10.1007/s40264-021-01077-9.
     
  2. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016: A study in the EGB database. Therapie. 2021 May-Jun;76(3):239-247. doi: 10.1016/j.therap.2020.07.002.
     
  3. Hurault-Delarue C, Araujo M, Vabre C, Benevent J, Damase-Michel C, Lacroix I. What changes in prescription patterns of antiemetic medications in pregnant women in France? Fundam Clin Pharmacol. 2021 Dec;35(6):1159-1167. doi: 10.1111/fcp.12681.
     
  4. Vabre C, Araujo M, Damase-Michel C, Hurault-Delarue C, Lacroix I. Initial data on the safety of metopimazine during pregnancy and the risk of major birth defects and pregnancy loss - An observational study using the EFEMERIS database. Therapie. 2021 Oct 7:S0040-5957(21)00203-1. doi: 10.1016/j.therap.2021.09.006. Epub ahead of print.
2020
Pas de publications

2019
  1. Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Benevent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, Lacroix I. Non-steroidal anti-inflammatory drug prescriptions from the 6th month of pregnancy: impact of advice from health authorities. Fundam Clin Pharmacol. 2019 Oct;33(5):581-588. doi: 10.1111/fcp.12460.
     
  2. Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C.  Pharmacoepidemiology in pregnancy. Therapie. 2019 Apr;74(2):289-300. doi: 10.1016/j.therap.2018.11.014.
     
  3. Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C.  Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2019 Jun;33(3):314-326. doi: 10.1111/fcp.12428
     
  4. Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C.  POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019 Jan;42(1):45-5 doi: 10.1007/s40264-018-0712-9.